Table of Contents Author Guidelines Submit a Manuscript
International Journal of Genomics
Volume 2014 (2014), Article ID 537969, 7 pages
http://dx.doi.org/10.1155/2014/537969
Research Article

Associations of CTLA4 Gene Polymorphisms with Graves’ Ophthalmopathy: A Meta-Analysis

1Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, China
2Department of Clinical Pharmacy, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, China

Received 5 May 2014; Accepted 18 June 2014; Published 9 July 2014

Academic Editor: Giulia Piaggio

Copyright © 2014 Pengfei Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Bahn and A. E. Heufelder, “Pathogenesis of Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 329, no. 20, pp. 1468–1475, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. T. F. Davies, A. Martin, E. S. Concepcion, P. Graves, L. Cohen, and A. Ben-Nun, “Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease,” The New England Journal of Medicine, vol. 325, no. 4, pp. 238–244, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. T. F. Davies, A. Martin, E. S. Conception et al., “Widespread Vβ and preferential VαT cell receptor gene utilization by intrathyroidal T cells in human autoimmune thyroid disease,” The Journal of Clinical Investigation, vol. 89, no. 1, pp. 157–162, 1992. View at Publisher · View at Google Scholar
  4. A. E. Heufelder, S. Herterich, G. Ernst, R. S. Bahn, and P. C. Scriba, “Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy,” European Journal of Endocrinology, vol. 132, no. 3, pp. 266–277, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Yanagawa, Y. Hidaka, V. Guimaraes, M. Soliman, and L. J. DeGroot, “CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 1, pp. 41–45, 1995. View at Google Scholar · View at Scopus
  6. T. Yanagawa, M. Taniyama, S. Enomoto et al., “CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese,” Thyroid, vol. 7, no. 6, pp. 843–846, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Heward, A. Allahabadia, M. Armitage et al., “The development of Graves' disease and the CTLA-4 gene on chromosome 2q33,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2398–2401, 1999. View at Google Scholar · View at Scopus
  8. B. Vaidya, H. Imrie, P. Perros et al., “The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus,” Human Molecular Genetics, vol. 8, no. 7, pp. 1195–1199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kouki, Y. Sawai, C. A. Gardine, M. E. Fisfalen, M. L. Alegre, and L. J. DeGroot, “CTLA-4 Gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease,” Journal of Immunology, vol. 165, no. 11, pp. 6606–6611, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Vaidya, H. Imrie, P. Perros et al., “Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy,” The Lancet, vol. 354, no. 9180, pp. 743–744, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Vaidya, E. J. C. Oakes, H. Imrie et al., “CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism,” Clinical Endocrinology, vol. 58, no. 6, pp. 732–735, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Buzzetti, L. Nistico, A. Signore, and I. Cascino, “CTLA-4 and HLA gene susceptibility to thyroid-associated orbitopathy,” The Lancet, vol. 354, no. 9192, p. 1824, 1999. View at Google Scholar · View at Scopus
  13. I. Frydecka, J. Daroszewski, K. Suwalska et al., “CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesia region,” Archivum Immunologiae et Therapiae Experimentalis, vol. 52, no. 5, pp. 369–374, 2004. View at Google Scholar · View at Scopus
  14. K. Badenhoop, H. Donner, J. Braun, T. Siegmund, H. Rau, and K. H. Usadel, “Genetic markers in diagnosis and prediction of relapse in Graves' disease,” Experimental and Clinical Endocrinology and Diabetes, vol. 104, no. 4, pp. 98–100, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. J. Park, H. K. Chung, D. J. Park et al., “Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans,” Thyroid, vol. 10, no. 6, pp. 453–459, 2000. View at Google Scholar · View at Scopus
  16. R. Villanueva, A. M. Inzerillo, Y. Tomer et al., “Limited genetic susceptibility to severe graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology,” Thyroid, vol. 10, no. 9, pp. 791–798, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Allahabadia, J. M. Heward, R. Nithiyananthan et al., “MHC class IIregion, CTLA4 gene, and ophthalmopathy in patients with Graves' disease,” The Lancet, vol. 358, no. 9286, pp. 984–985, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Zaletel, B. Krhin, S. Gaberšček, E. Pirnat, and S. Hojker, “The influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease,” Thyroid, vol. 12, no. 5, pp. 373–376, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Bednarczuk, Y. Hiromatsu, T. Fukutani et al., “Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations,” European Journal of Endocrinology, vol. 148, no. 1, pp. 13–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Petrone, G. Giorgi, A. Galgani et al., “CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte- associated antigen-4 gene region is associated with graves' disease in an Italian population,” Thyroid, vol. 15, no. 3, pp. 232–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Han, S. Zhang, W. Zhang et al., “CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis,” Human Immunology, vol. 67, no. 8, pp. 618–626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Zhang, Y. M. Yang, and X. Y. Lv, “Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene,” Journal of Zhejiang University: Science B, vol. 7, no. 11, pp. 887–891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. K. K. Chong, S. W. Chiang, G. W. Wong et al., “Association of CTLA-4 and IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in Chinese children,” Investigative Ophthalmology and Visual Science, vol. 49, no. 6, pp. 2409–2415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Esteghamati, O. Khalilzadeh, Z. Mobarra et al., “Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients,” European Journal of Internal Medicine, vol. 20, no. 4, pp. 424–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lau, J. P. A. Ioannidis, and C. H. Schmid, “Quantitative synthesis in systematic reviews,” Annals of Internal Medicine, vol. 127, no. 9, pp. 820–826, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. D. B. Petitti, Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis, Oxford University Press, New York, NY, USA, 1994.
  27. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at Scopus
  28. J. Daroszewski, E. Pawlak, L. Karabon et al., “Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms,” European Journal of Endocrinology, vol. 161, no. 5, pp. 787–793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Z. Han, S. H. Zhang, R. Li, W. Y. Zhang, and Y. Li, “The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients,” International Journal of Immunogenetics, vol. 33, no. 4, pp. 281–287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M. C. Tessier, and C. Polychronakos, “A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele,” The Journal of Biological Chemistry, vol. 277, no. 48, pp. 46478–46486, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Takara, T. Kouki, and L. J. DeGroot, “CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease,” Thyroid, vol. 13, no. 12, pp. 1083–1089, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Ban, T. F. Davies, D. A. Greenberg et al., “Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease,” Genes and Immunity, vol. 4, no. 8, pp. 586–593, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. E. M. Jacobson, S. Chaudhry, J. C. Mandac, E. Concepcion, and Y. Tomer, “Immune regulatory gene involvement in the etiology of interferon induced thyroiditis (IIT),” Thyroid, vol. 16, no. 9, article 926, 2006. View at Google Scholar
  34. Y. Xu, P. N. Graves, Y. Tomer, and T. F. Davies, “CTLA-4 and autoimmune thyroid disease: lack of influence of the A49G signal peptide polymorphism on functional recombinant human CTLA-4,” Cellular Immunology, vol. 215, no. 2, pp. 133–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Hagg and K. Asplund, “Is endocrine ophthalmopathy related to smoking?” The British Medical Journal, vol. 295, no. 6599, pp. 634–635, 1987. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Pfeilschifter and R. Ziegler, “Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption,” Clinical Endocrinology, vol. 45, no. 4, pp. 477–481, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Shine, P. Fells, O. M. Edwards, and A. P. Weetman, “Association between Graves' ophthalmopathy and smoking,” The Lancet, vol. 335, no. 8700, pp. 1261–1263, 1990. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Bielekova and R. Martin, “Antigen-specific immunomodulation via altered peptide ligands,” Journal of Molecular Medicine, vol. 79, no. 10, pp. 552–565, 2001. View at Publisher · View at Google Scholar · View at Scopus